Inspire Medical Systems swings to Q3 net loss of $24.4 million
INSP•Inspire Medical Systems reported a third-quarter net loss of $24.4 million, compared with year-earlier net income of $9.93 million, as revenue fell 8% to $206.7 million. It narrowed 2026 revenue guidance to $850 million–$860 million and plans for a return to growth in 2027.
1. Quarterly results and outlook
Inspire Medical Systems swung to a third-quarter 2026 net loss of $24.4 million from a profit of $9.93 million a year earlier. Revenue fell 8% year over year to $206.7 million, primarily due to U.S. coding and reimbursement challenges. The company narrowed its full-year 2026 revenue guidance to $850 million–$860 million from $835 million–$875 million, and management plans for a return to growth in 2027. New Category I CPT codes covering single-lead hypoglossal nerve stimulation, including Inspire V, take effect January 1, 2028.
